Estradiol Transdermal System, USP (Twice-Weekly) 0.0375mg/day, Rx Only, Manufactured by: Cadila H...

FDA Recall #D-0542-2024 — Class III — May 16, 2024

Recall #D-0542-2024 Date: May 16, 2024 Classification: Class III Status: Ongoing

Product Description

Estradiol Transdermal System, USP (Twice-Weekly) 0.0375mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1192-8

Reason for Recall

Failed Impurities/Degradation Specifications.

Recalling Firm

Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

21,360 units

Distribution

Nationwide within the United States

Code Information

Lot #: M310493, Exp. Date 01/2025; M308397, Exp. Date 11/2024; M305337, Exp. Date 10/2024; M400155, Exp. Date 06/2025; M314660, Exp. Date 05/2025

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated